Digitale Bibliotheek
Sluiten Bladeren door artikelen uit een tijdschrift
 
Zoeken naar met titel:
ABCDEFGHIJKLMNOPQRSTUVWXYZ

     Tijdschrift beschrijving
       Alle jaargangen van het bijbehorende tijdschrift
         Alle afleveringen van het bijbehorende jaargang
                                       Alle artikelen van de bijbehorende aflevering
 
                             226 gevonden resultaten
nr titel auteur tijdschrift jaar jaarg. afl. pagina('s) type
1 Abdominal sacral colpopexy and abdominal enterocele repair in the management of vaginal vault prolapse Winters, J.Christian
 2000
 1-20 6S1 p. 55-63
9 p.
 artikel
2 Ablation of uroplakin III gene results in small urothelial plaques, urothelial leakage, and vesicoureteral reflux Hu, P
 2001
 1-20 6S1 p. 117-
1 p.
 artikel
3 Advancements in pharmacologic management of the overactive bladder Dmochowski, Roger R
 2000
 1-20 6S1 p. 41-49
9 p.
 artikel
4 A laboratory stress model for examining stress and symptomatology in interstitial cystitis patients Lutgendorf, S.K
 2001
 1-20 6S1 p. 122-
1 p.
 artikel
5 Alfuzosin: overview of pharmacokinetics, safety, and efficacy of a clinically uroselective α-blocker Roehrborn, Claus G
 2001
 1-20 6S1 p. 55-63
9 p.
 artikel
6 Alkalinized intravesical lidocaine to treat interstitial cystitis: absorption kinetics in normal and interstitial cystitis bladders Henry, R.A
 2001
 1-20 6S1 p. 119-
1 p.
 artikel
7 A myogenic basis for the overactive bladder Brading, Alison F.
 1997
 1-20 6S1 p. 57-67
11 p.
 artikel
8 Analysis of percent free prostate-specific antigen (PSA) for prostate cancer detection: Influence of total psa, prostate volume, and age Partin, Alan W.
 1996
 1-20 6S1 p. 55-61
7 p.
 artikel
9 A neurologic basis for the overactive bladder de Groat, William C.
 1997
 1-20 6S1 p. 36-52
17 p.
 artikel
10 A new technique for cystocele repair and transvaginal sling: the cadaveric prolapse repair and sling (CaPS) Kobashi, Kathleen C
 2000
 1-20 6S1 p. 9-14
6 p.
 artikel
11 Anterior approach bilateral sacrospinous ligament fixation for vaginal vault prolapse 1 1 The opinions expressed herein are those of the authors and do not necessarily reflect those of the Departments of the Army, Air Force, or Defense. Cespedes, R.Duane
 2000
 1-20 6S1 p. 70-75
6 p.
 artikel
12 Anti-androgens and other hormonal therapies for prostate cancer Richie, Jerome P
 1999
 1-20 6S1 p. 15-18
4 p.
 artikel
13 Antiandrogens: Preclinical and clinical studies Neri, Rudolph O.
 1994
 1-20 6S1 p. 53-60
8 p.
 artikel
14 Antiproliferative factor, heparin-binding epidermal growth factor–like growth factor, and epidermal growth factor: sensitive and specific urine markers for interstitial cystitis Keay, S
 2001
 1-20 6S1 p. 104-
1 p.
 artikel
15 Appropriate Patient Selection in the Focal Treatment of Prostate Cancer: The Role of Transperineal 3-Dimensional Pathologic Mapping of the Prostate—A 4-Year Experience Barzell, Winston E.
 2007
 1-20 6S1 p. S27-S35
9 p.
 artikel
16 Are glomerulations present in patients of other diseases? Mishra, N
 2001
 1-20 6S1 p. 125-126
2 p.
 artikel
17 A reliable, nondestructive animal model for interstitial cystitis: intravesical low-dose protamine sulfate combined with physiological concentrations of potassium chloride Fraser, M.O
 2001
 1-20 6S1 p. 112-
1 p.
 artikel
18 Assessment of murine bladder permeability with fluorescein: validation with cyclophosphamide and protamine Eichel, L
 2001
 1-20 6S1 p. 115-
1 p.
 artikel
19 Automated noninvasive measurement of cyclophosphamide-induced changes in murine micturition frequency and volume and demonstration of pharmacologic sensitivity Wood, R
 2001
 1-20 6S1 p. 115-116
2 p.
 artikel
20 Basic science research on the urinary bladder and interstitial cystitis: new genetic approaches Liebert, Monica
 2001
 1-20 6S1 p. 7-8
2 p.
 artikel
21 Biopsy features are associated with primary symptoms in interstitial cystitis: results from the interstitial cystitis database study Tomaszewski, John E.
 2001
 1-20 6S1 p. 67-81
15 p.
 artikel
22 Bladder cancer: Epidemiology, staging and grading, and diagnosis Kirkali, Ziya
 2005
 1-20 6S1 p. 4-34
31 p.
 artikel
23 Bladder hypersensitivity of interstitial cystitis complicated by allergic diseases Yamada, T
 2001
 1-20 6S1 p. 125-
1 p.
 artikel
24 Bladder instillation of “naked” hSlo/pcDNA3 ameliorates detrusor hyperactivity in obstructed rats in vivo Christ, G.J
 2001
 1-20 6S1 p. 111-
1 p.
 artikel
25 Bladder microvasculature and the effects of hydrodistention in interstitial cystitis Rosamilia, A
 2001
 1-20 6S1 p. 132-
1 p.
 artikel
26 Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers Lokeshwar, Vinata B.
 2005
 1-20 6S1 p. 35-63
29 p.
 artikel
27 Calcium signaling in cultured human detrusor smooth muscle cells from patients with interstitial cystitis Bouchelouche, K
 2001
 1-20 6S1 p. 109-110
2 p.
 artikel
28 cDNA array of lipopolysaccharide-induced bladder gene expression Saban, M.R
 2001
 1-20 6S1 p. 117-
1 p.
 artikel
29 cDNA expression arrays: the effects of lactacystin in lipopolysaccharide-induced cystitis Wang, X.C
 2001
 1-20 6S1 p. 114-115
2 p.
 artikel
30 Changes in electrical properties of detrusor smooth muscle in the STZ (streptozotocin)–diabetic rat Karicheti, V
 2001
 1-20 6S1 p. 110-111
2 p.
 artikel
31 Changing concepts in the management of advanced prostate cancer Crawford, E. David
 1994
 1-20 6S1 p. 67-74
8 p.
 artikel
32 Chemotherapy Followed by Syngeneic Dendritic Cell Injection in the Mouse: Findings and Implications for Human Treatment Cavanagh, William A.
 2007
 1-20 6S1 p. S36-S41
6 p.
 artikel
33 Chemotherapy for advanced hormone refractory prostate cancer Petrylak, Daniel P
 1999
 1-20 6S1 p. 30-35
6 p.
 artikel
34 Chlorpactin instillation releases calcitonin gene-related peptide in interstitial cystitis patients Kreder, K
 2001
 1-20 6S1 p. 128-129
2 p.
 artikel
35 Clinical characteristics support that interstitial cystitis is a heterogeneous syndrome Fall, M
 2001
 1-20 6S1 p. 129-130
2 p.
 artikel
36 Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: A pooled analysis Appell, Rodney A.
 1997
 1-20 6S1 p. 90-96
7 p.
 artikel
37 Clinical highlights of the national institute of diabetes and digestive and kidney diseases/interstitial cystitis association scientific conference on interstitial cystitis Hanno, Philip M
 2001
 1-20 6S1 p. 2-6
5 p.
 artikel
38 Closing remarks Wein, Alan J.
 1997
 1-20 6S1 p. 114-
1 p.
 artikel
39 CME Assessment Test and Evaluation Form 2001
 1-20 6S1 p. 79-82
4 p.
 artikel
40 CME sponsorship, objectives, disclosure 2001
 1-20 6S1 p. iv-v
nvt p.
 artikel
41 Comparison of three assays for total serum prostate-specific antigen and percentage of free prostate-specific antigen in predicting prostate histology Roehrborn, Claus G.
 1996
 1-20 6S1 p. 23-32
10 p.
 artikel
42 Complications of advanced prostate cancer Smith Jr., Joseph A
 1999
 1-20 6S1 p. 8-14
7 p.
 artikel
43 Concordance of interstitial cystitis (IC) in identical twins: preliminary data Warren, J.
 2001
 1-20 6S1 p. 126-
1 p.
 artikel
44 Concordance of interstitial cystitis in monozygotic and dizygotic twin pairs Warren, John W
 2001
 1-20 6S1 p. 22-25
4 p.
 artikel
45 Contemporary expectant therapy series: A viewpoint Schellhammer, Paul F.
 1994
 1-20 6S1 p. 47-52
6 p.
 artikel
46 Continuous bladder infusion methods for studying voiding function in ambulatory mice Eichel, L.S
 2001
 1-20 6S1 p. 115-
1 p.
 artikel
47 Correlation of symptoms between 2 instruments among interstitial cystitis patients Sirinian, E
 2001
 1-20 6S1 p. 124-125
2 p.
 artikel
48 Corticotropin-releasing hormone perturbations in interstitial cystitis patients: evidence for abnormal sympathetic activity Dimitrakov, J
 2001
 1-20 6S1 p. 128-
1 p.
 artikel
49 Current controversies that adversely affect interstitial cystitis patients Ratner, Vicki
 2001
 1-20 6S1 p. 89-94
6 p.
 artikel
50 Cysteinyl-leukotriene D4 receptors in smooth muscle cells Bouchelouche, K
 2001
 1-20 6S1 p. 109-
1 p.
 artikel
51 Cystistat for the treatment of interstitial cystitis: a 3-year follow-up study Nordling, J
 2001
 1-20 6S1 p. 123-
1 p.
 artikel
52 Daily stress and symptom exacerbation in interstitial cystitis patients Rothrock, N.E
 2001
 1-20 6S1 p. 122-
1 p.
 artikel
53 Defining overactive bladder: Epidemiology and burden of disease Tubaro, Andrea
 2004
 1-20 6S1 p. 2-6
5 p.
 artikel
54 Definition of overactive bladder and epidemiology of urinary incontinence Hampel, C.
 1997
 1-20 6S1 p. 4-14
11 p.
 artikel
55 Diagnosis and significance of idiopathic overactive bladder Artibani, Walter
 1997
 1-20 6S1 p. 25-32
8 p.
 artikel
56 Discussion: A framework for diagnosis of idiopathic overactive bladder Blaivas, Jerry G.
 1997
 1-20 6S1 p. 34-
1 p.
 artikel
57 Discussion: A link between peripheral and central neural mechanisms: Nerve growth factor Steers, William D.
 1997
 1-20 6S1 p. 54-55
2 p.
 artikel
58 Discussion: A neurologic basis for the overactive bladder: Focus on brain function Griffiths, Derek J.
 1997
 1-20 6S1 p. 53-
1 p.
 artikel
59 Discussion: Assessment of symptoms in patients with an overactive bladder Nishizawa, Osamu
 1997
 1-20 6S1 p. 23-
1 p.
 artikel
60 Discussion: Cellular physiology of detrusor smooth muscle and the development of bladder instability: Possible mechanisms Fry, Christopher H.
 1997
 1-20 6S1 p. 70-71
2 p.
 artikel
61 Discussion: C-fiber afferents and reflex processing in the rat Morrison, John F.B.
 1997
 1-20 6S1 p. 55-56
2 p.
 artikel
62 Discussion: Challenges in the economic evaluation of incontinence services Drummond, Michael F.
 1997
 1-20 6S1 p. 108-
1 p.
 artikel
63 Discussion: Drug treatment for urge incontinence in the elderly Malone-Lee, James
 1997
 1-20 6S1 p. 86-
1 p.
 artikel
64 Discussion: Effects of urethral obstruction on guinea pig bladder muscle Mostwin, Jacek L.
 1997
 1-20 6S1 p. 68-70
3 p.
 artikel
65 Discussion: Epidemiology of urinary incontinence Bump, Richard C.
 1997
 1-20 6S1 p. 15-17
3 p.
 artikel
66 Discussion following Dr. Barry’s presentation 2001
 1-20 6S1 p. 32-
1 p.
 artikel
67 Discussion following Dr. Blute’S presentation 2001
 1-20 6S1 p. 40-41
2 p.
 artikel
68 Discussion following Dr. Jacobsen’s presentation 2001
 1-20 6S1 p. 16-
1 p.
 artikel
69 Discussion following Dr. Kaplan’s presentation 2001
 1-20 6S1 p. 70-
1 p.
 artikel
70 Discussion following Dr. Lowe’s presentation 2001
 1-20 6S1 p. 76-77
2 p.
 artikel
71 Discussion following Dr. O’Leary’s presentation 2001
 1-20 6S1 p. 48-
1 p.
 artikel
72 Discussion following Dr. Roehrborn’s presentation 2001
 1-20 6S1 p. 63-64
2 p.
 artikel
73 Discussion following Dr. Steers’ presentation 2001
 1-20 6S1 p. 24-
1 p.
 artikel
74 Discussion: Functional classification of the overactive bladder Fall, M.
 1997
 1-20 6S1 p. 34-35
2 p.
 artikel
75 Discussion: Idiopathic overactive bladder function Van Waalwijk Van Doorn, E.S.C.
 1997
 1-20 6S1 p. 33-
1 p.
 artikel
76 Discussion: Method of evaluating tolterodine efficacy in phase II Japanese study Kawabe, Kazuki
 1997
 1-20 6S1 p. 98-99
2 p.
 artikel
77 Discussion: Potential future pharmacologic approaches Levin, Robert M.
 1997
 1-20 6S1 p. 87-89
3 p.
 artikel
78 Discussion: Quality of life in patients with overactive bladder Norton, Chritine
 1997
 1-20 6S1 p. 23-24
2 p.
 artikel
79 Discussion: The effect of estrogens Cardozo, Linda
 1997
 1-20 6S1 p. 85-
1 p.
 artikel
80 Discussion: The neostructural myogenic mechanism of detrusor overactivity Elbadawi, Ahmad
 1997
 1-20 6S1 p. 71-73
3 p.
 artikel
81 Discussion: Theoretical and practical considerations in modeling outcomes in urge urinary incontinence Resnick, Neil M.
 1997
 1-20 6S1 p. 109-110
2 p.
 artikel
82 Discussion: Tolterodine for treatment of the overactive bladder Norton, Peggy A.
 1997
 1-20 6S1 p. 97-
1 p.
 artikel
83 Does free to total ratio of prostate-specific antigen alter decision-making on prostatic biopsy? Alivizatos, Gerasimos
 1996
 1-20 6S1 p. 71-75
5 p.
 artikel
84 Down-staging of early stage prostate cancer before radical prostatectomy: The first randomized trial of neoadjuvant combination therapy with flutamide and a luteinizing hormone-releasing hormone agonist Labrie, Fernand
 1994
 1-20 6S1 p. 29-37
9 p.
 artikel
85 Dynamic interactions between host and pathogen during acute urinary tract infections Schilling, Joel D
 2001
 1-20 6S1 p. 56-61
6 p.
 artikel
86 Economic considerations and outcome measurement in urge incontinence Kobelt, Gisela
 1997
 1-20 6S1 p. 100-107
8 p.
 artikel
87 Effect of digital rectal examination on monoclonal hybritech and polyclonal yang prostatic-SPECIFIC antigen Talley, David R.
 1994
 1-20 6S1 p. 26-28
3 p.
 artikel
88 Effect of mast cell granules on urinary tract epithelial cells in culture Rickard, A
 2001
 1-20 6S1 p. 114-
1 p.
 artikel
89 Effect of physiologic levels of urinary potassium on interstitial cystitis symptoms Payne, C.K
 2001
 1-20 6S1 p. 124-
1 p.
 artikel
90 Effects of CP55,940 and methanadamide on detrusor activity Theobald Jr, R.J
 2001
 1-20 6S1 p. 125-
1 p.
 artikel
91 Effects of resiniferatoxin on the neurogenic component of feline interstitial cystitis March, P
 2001
 1-20 6S1 p. 114-
1 p.
 artikel
92 Epidemiology of prostate cancer Crawford, E.David
 2003
 1-20 6S1 p. 3-12
10 p.
 artikel
93 Estrogen and neuroinflammation Bjorling, Dale E
 2001
 1-20 6S1 p. 40-46
7 p.
 artikel
94 Evaluation of symptoms and quality of life in men with benign prostatic hyperplasia Barry, Michael J
 2001
 1-20 6S1 p. 25-32
8 p.
 artikel
95 Evaluation of transvaginal theile massage as a therapeutic intervention for women with interstitial cystitis Holzberg, A
 2001
 1-20 6S1 p. 120-
1 p.
 artikel
96 Evolution of therapeutic approaches with luteinizing hormone–releasing hormone agonists in 2003 1 1 Judd W. Moul has been a member of the Speaker's Bureau for AstraZeneca, Bayer, and TAP, and is a study investigator funded by AstraZeneca Moul, Judd W
 2003
 1-20 6S1 p. 20-28
9 p.
 artikel
97 Exploring the effects of luteinizing hormone–releasing hormone agonist therapy on bone health: implications in the management of prostate cancer Chang, SAM S
 2003
 1-20 6S1 p. 29-35
7 p.
 artikel
98 Fishbein/interstitial cystitis association (ICA) survey of interstitial cystitis among family members of ICA members: preliminary analysis Warren, J.
 2001
 1-20 6S1 p. 126-127
2 p.
 artikel
99 Focal Cryosurgery Followed by Penile Rehabilitation as Primary Treatment for Localized Prostate Cancer: Initial Results Ellis, David S.
 2007
 1-20 6S1 p. S9-S15
7 p.
 artikel
100 Follow-up evaluation of national prostatic cancer project protocols and other studies Murphy, Gerald P.
 1994
 1-20 6S1 p. 61-66
6 p.
 artikel
101 Free and complexed prostate-specific antigen serum ratios to predict probability of primary prostate cancer and benign prostatic hyperplasia Marley, Garry M.
 1996
 1-20 6S1 p. 16-22
7 p.
 artikel
102 Free to total Prostate-Specific Antigen (PSA) ratio improves the discrimination between prostate cancer and benign prostatic hyperplasia (BPH) in the diagnostic gray zone of 1.8 to 10 ng/mL total PSA Van Cangh, Paul J.
 1996
 1-20 6S1 p. 67-70
4 p.
 artikel
103 Gap junction channel activity in cultured human bladder smooth muscle cell pairs: gating and unitary conductances Wang, H.-Z
 2001
 1-20 6S1 p. 111-
1 p.
 artikel
104 Gene-regulation during bladder neurogenic inflammation Saban, R
 2001
 1-20 6S1 p. 103-
1 p.
 artikel
105 Gene therapy of bladder pain with herpes simplex virus (HSV) vectors expressing preproenkephalin (PPE) Yoshimura, N
 2001
 1-20 6S1 p. 116-
1 p.
 artikel
106 Group Consensus Reports from the Consensus Conference on Focal Treatment of Prostatic Carcinoma, Celebration, Florida, February 24, 2006 Bostwick, David G.
 2007
 1-20 6S1 p. S42-S44
3 p.
 artikel
107 Half-life determination of serum free prostate-specific antigen following radical retropubic prostatectomy Richardson, Thomas D.
 1996
 1-20 6S1 p. 40-44
5 p.
 artikel
108 Hemidesmosomes in bladder epithelial cells Jones, J.C.R
 2001
 1-20 6S1 p. 103-
1 p.
 artikel
109 High-grade Ta urothelial carcinoma and carcinoma in situ of the bladder Sylvester, Richard J.
 2005
 1-20 6S1 p. 90-107
18 p.
 artikel
110 Hormonal pretreatment does not affect the final pathologic stage in locally advanced prostate cancer Pummer, Karl
 1994
 1-20 6S1 p. 38-42
5 p.
 artikel
111 Human bladder permeability assessment using intravesical fluorescein clearance rate Wood, R
 2001
 1-20 6S1 p. 131-132
2 p.
 artikel
112 Immunologic and neurobiologic characteristics support that interstitial cystitis is a heterogeneous syndrome Peeker, R
 2001
 1-20 6S1 p. 130-
1 p.
 artikel
113 Impact of free prostate-specific antigen on discordant measurement results of assays for total prostate-specific antigen Semjonow, Axel
 1996
 1-20 6S1 p. 10-15
6 p.
 artikel
114 Inauguration of the Prostate Cancer Focal Therapy Debate Bostwick, David G.
 2007
 1-20 6S1 p. S1-S2
2 p.
 artikel
115 Increased plasma norepinephrine concentrations in cats with interstitial cystitis Buffington, T
 2001
 1-20 6S1 p. 102-
1 p.
 artikel
116 Increased urinary excretion of leukotriene E4 in patients with interstitial cystitis Bouchelouche, K
 2001
 1-20 6S1 p. 128-
1 p.
 artikel
117 Injectable agents in the treatment of stress urinary incontinence in women: where are we now? Dmochowski, Roger R.
 2000
 1-20 6S1 p. 32-40
9 p.
 artikel
118 Interstitial cystitis: a chronic visceral pain syndrome Wesselmann, Ursula
 2001
 1-20 6S1 p. 32-39
8 p.
 artikel
119 Interstitial cystitis: a chronic visceral pain syndrome Wesselmann, U
 2001
 1-20 6S1 p. 102-
1 p.
 artikel
120 Interstitial cystitis: a proposal on cardinal symptoms and signs Mortensen, S
 2001
 1-20 6S1 p. 122-
1 p.
 artikel
121 Interstitial cystitis: current issues and controversies in diagnosis Sant, Grannum R
 2001
 1-20 6S1 p. 82-88
7 p.
 artikel
122 Interstitial cystitis in children: not a rare entity Schuster, G.A
 2001
 1-20 6S1 p. 107-
1 p.
 artikel
123 Interstitial cystitis in India: important lessons Mishra, N
 2001
 1-20 6S1 p. 107-108
2 p.
 artikel
124 Interstitial cystitis in males Indudhara, R
 2001
 1-20 6S1 p. 120-121
2 p.
 artikel
125 Interstitial cystitis: past and future Steers, W.D
 2001
 1-20 6S1 p. 101-102
2 p.
 artikel
126 Intravesical ultrapotent vanilloid receptor agonists: acute effects on animal models of bladder irritation Fraser, M.O
 2001
 1-20 6S1 p. 111-112
2 p.
 artikel
127 Introduction Crawford, E.David
 2003
 1-20 6S1 p. 1-2
2 p.
 artikel
128 Introduction Blute, Michael L.
 2001
 1-20 6S1 p. 1-4
4 p.
 artikel
129 Introduction Cespedes, R.Duane
 2000
 1-20 6S1 p. 1-
1 p.
 artikel
130 Introduction Hanno, Philip M
 2001
 1-20 6S1 p. 1-
1 p.
 artikel
131 Introduction Soloway, Mark S.
 2005
 1-20 6S1 p. 1-3
3 p.
 artikel
132 Introduction Tubaro, Andrea
 2004
 1-20 6S1 p. 1-
1 p.
 artikel
133 Introduction David Crawford, E.
 1994
 1-20 6S1 p. 1-
1 p.
 artikel
134 Introduction to the overactive bladder: From basic science to clinical management Abrams, Paul
 1997
 1-20 6S1 p. 1-3
3 p.
 artikel
135 In vitro stability of free prostate-specific antigen (PSA) and prostate-specific antigen (PSA) complexed to α1-antichymotrypsin in blood samples Piironen, Timo
 1996
 1-20 6S1 p. 81-87
7 p.
 artikel
136 Is interstitial cystitis an underdiagnosed problem in children? A diagnostic and therapeutic dilemma Park, John M
 2001
 1-20 6S1 p. 30-31
2 p.
 artikel
137 Is There a Better Way to Biopsy the Prostate? Prospects for a Novel Transrectal Systematic Biopsy Approach Andriole, Gerald L.
 2007
 1-20 6S1 p. S22-S26
5 p.
 artikel
138 KATP channel currents regulate membrane potential in freshly isolated human and rat bladder smooth muscle cells Wang, H.-Z
 2001
 1-20 6S1 p. 110-
1 p.
 artikel
139 Laparoscopic paravaginal repair plus burch colposuspension: review and descriptive technique Miklos, John R
 2000
 1-20 6S1 p. 64-69
6 p.
 artikel
140 Longitudinal analysis of serial measurements of free and total PSA among men with and without prostatic cancer Pearson, Jay D.
 1996
 1-20 6S1 p. 4-9
6 p.
 artikel
141 Long-term effects of urea on urothelial barrier function Lewis, S.A
 2001
 1-20 6S1 p. 113-
1 p.
 artikel
142 Long-term results of a multicenter study on sacral nerve stimulation for treatment of urinary urge incontinence, urgency-frequency, and retention Siegel, Steven W.
 2000
 1-20 6S1 p. 87-91
5 p.
 artikel
143 Low-grade Ta (noninvasive) urothelial carcinoma of the bladder Oosterlinck, Willem
 2005
 1-20 6S1 p. 75-89
15 p.
 artikel
144 Luteinizing hormone–releasing hormone agonists in the treatment of men with prostate cancer: timing, alternatives, and the 1-year implant Marks, LEONARD S
 2003
 1-20 6S1 p. 36-42
7 p.
 artikel
145 “Male Lumpectomy”: Focal Therapy for Prostate Cancer Using Cryoablation Onik, Gary
 2007
 1-20 6S1 p. S16-S21
6 p.
 artikel
146 Management of overactive bladder—Looking to the future Mattiasson, Anders
 1997
 1-20 6S1 p. 111-113
3 p.
 artikel
147 Management of stage T1 tumors of the bladder: International Consensus Panel Nieder, Alan M.
 2005
 1-20 6S1 p. 108-125
18 p.
 artikel
148 Mast cell enzymes alter the connective tissue phenotype of bladder wall fibroblasts and smooth muscle cells Howard, P.S
 2001
 1-20 6S1 p. 112-113
2 p.
 artikel
149 Mast cell involvement in interstitial cystitis: a review of human and experimental evidence Theoharides, Theoharis C
 2001
 1-20 6S1 p. 47-55
9 p.
 artikel
150 Medical therapy in interstitial cystitis: the essex experience Lewi, H
 2001
 1-20 6S1 p. 120-
1 p.
 artikel
151 Minimally invasive therapies for benign prostatic hyperplasia Blute, Michael L.
 2001
 1-20 6S1 p. 33-40
8 p.
 artikel
152 Multicenter comparison of the diagnostic performance of free prostate-specific antigen Thiel, Robert P.
 1996
 1-20 6S1 p. 45-50
6 p.
 artikel
153 Natural history of benign prostatic hyperplasia Jacobsen, Steven J
 2001
 1-20 6S1 p. 5-16
12 p.
 artikel
154 Observations on the epidemiology and natural history of prostate cancer Montie, James E.
 1994
 1-20 6S1 p. 2-8
7 p.
 artikel
155 Observations on the management of interstitial cystitis in men Forrest, J
 2001
 1-20 6S1 p. 107-
1 p.
 artikel
156 Observations on the presentation, diagnosis, and treatment of interstitial cystitis in men Forrest, John B
 2001
 1-20 6S1 p. 26-29
4 p.
 artikel
157 Outcome in 104 pubovaginal slings using freeze-dried allograft fascia lata from a single tissue bank Amundsen, C.L
 2000
 1-20 6S1 p. 2-8
7 p.
 artikel
158 Overexpression of platelet-derived endothelial cell growth factor (PD-ECGF) factor/thymidine phosphorylase (TP) in interstitial cystitis Ueda, T
 2001
 1-20 6S1 p. 130-131
2 p.
 artikel
159 Overview: hormone refractory prostate cancer Crawford, E.David
 1999
 1-20 6S1 p. 1-7
7 p.
 artikel
160 Phytotherapy in the management of benign prostatic hyperplasia Lowe, Franklin C.
 2001
 1-20 6S1 p. 71-76
6 p.
 artikel
161 Plasticity of the urothelial phenotype: effects of gastrointestinal mesenchyme/stroma and implications for urinary tract reconstruction Baskin, L.S
 2001
 1-20 6S1 p. 104-
1 p.
 artikel
162 Positive and negative regulators of human urothelial cell proliferation Bassuk, J.A
 2001
 1-20 6S1 p. 104-105
2 p.
 artikel
163 Practice trends for the management of interstitial cystitis Gershbaum, D
 2001
 1-20 6S1 p. 119-
1 p.
 artikel
164 Preoperative Prediction of Multifocal Prostate Cancer and Application of Focal Therapy: Review 2007 Meiers, Isabelle
 2007
 1-20 6S1 p. S3-S8
6 p.
 artikel
165 Prognostic markers for bladder cancer: International Consensus Panel on bladder tumor markers Habuchi, Tomonori
 2005
 1-20 6S1 p. 64-74
11 p.
 artikel
166 Prospective use of free prostate-specific antigen to avoid repeat prostate biopsies in men with elevated total prostate-specific antigen Morgan, Ted O.
 1996
 1-20 6S1 p. 76-80
5 p.
 artikel
167 Prostate-specific antigen: Critical issues Brawer, MICHAEL K.
 1994
 1-20 6S1 p. 9-17
9 p.
 artikel
168 Protamine sulfate-induced cystitis: a model of selective cytodestruction of the urothelium Lavelle, J
 2001
 1-20 6S1 p. 113-
1 p.
 artikel
169 Psychometric validation of the O’leary-Sant interstitial cystitis symptom index in a clinical trial of pentosan polysulfate sodium Lubeck, Deborah P
 2001
 1-20 6S1 p. 62-66
5 p.
 artikel
170 Recent advances in the management of the neurogenic bladder Elliott, Daniel S
 2000
 1-20 6S1 p. 76-81
6 p.
 artikel
171 Recombinant human nerve growth factor in the treatment of interstitial cystitis: preliminary results Dimitrakov, J
 2001
 1-20 6S1 p. 118-119
2 p.
 artikel
172 5α-reductase activity in the prostate Steers, William D.
 2001
 1-20 6S1 p. 17-24
8 p.
 artikel
173 5α-reductase inhibitors: what role should they play? Kaplan, Steven A
 2001
 1-20 6S1 p. 65-70
6 p.
 artikel
174 Review of phase II hormone refractory prostate cancer trials Murphy, Gerald P
 1999
 1-20 6S1 p. 19-21
3 p.
 artikel
175 Role of prostaglandins in bladder smooth muscle cell gene expression Park, J.M
 2001
 1-20 6S1 p. 105-
1 p.
 artikel
176 RTX exotoxins Chancellor, M.B.
 2001
 1-20 6S1 p. 106-107
2 p.
 artikel
177 Sacral nerve stimulation as a treatment for urge incontinence and associated pelvic floor disorders at a pelvic floor center: a follow-up study Caraballo, R
 2001
 1-20 6S1 p. 121-
1 p.
 artikel
178 Sacral nerve stimulation in patients with chronic, intractable pelvic pain Paszkiewicz, E.J.
 2001
 1-20 6S1 p. 124-
1 p.
 artikel
179 Safety and efficacy of up to 900 mg/day polysulfate sodium (elmiron) in patients with interstitial cystitis Nickel, J.C.
 2001
 1-20 6S1 p. 122-123
2 p.
 artikel
180 Screening for prostate cancer by digital rectal examination and prostate-specific antigen Stone, Nelson N.
 1994
 1-20 6S1 p. 18-25
8 p.
 artikel
181 Sensitivity and specificity of antiproliferative factor, heparin-binding epidermal growth factor–like growth factor, and epidermal growth factor as urine markers for interstitial cystitis Keay, Susan K
 2001
 1-20 6S1 p. 9-14
6 p.
 artikel
182 Stability of free prostate-specific antigen in serum samples under a variety of sample collection and sample storage conditions Woodrum, David
 1996
 1-20 6S1 p. 33-39
7 p.
 artikel
183 Stimulation of human urothelial cell proliferation by estrogen receptor activation Teng, J
 2001
 1-20 6S1 p. 102-103
2 p.
 artikel
184 Stretch-activated release of adenosine triphosphate by bladder uroepithelia is augmented in interstitial cystitis Sun, Y.
 2001
 1-20 6S1 p. 131-
1 p.
 artikel
185 Stretch-induced bladder smooth muscle cell (SMC) proliferation is mediated by RHAMM-dependent extracellular-regulated kinase (erk) signaling Aitken, K
 2001
 1-20 6S1 p. 109-
1 p.
 artikel
186 Stretch-regulated exocytosis of discoidal vesicles in urinary bladder epithelium Apodaca, G
 2001
 1-20 6S1 p. 103-104
2 p.
 artikel
187 Strontium-89 in metastatic prostate cancer Porter, Arthur T
 1994
 1-20 6S1 p. 75-80
6 p.
 artikel
188 Summary: the role of the urologist in chemotherapy of hormone refractory prostate cancer Crawford, E.David
 1999
 1-20 6S1 p. 51-52
2 p.
 artikel
189 Suppression of the tetrodotoxin-resistant sodium channel (PN3/SNS): a possible new treatment for bladder pain Yoshimura, N
 2001
 1-20 6S1 p. 116-117
2 p.
 artikel
190 Symptom reports among interstitial cystitis patients Stoney, C
 2001
 1-20 6S1 p. 127-
1 p.
 artikel
191 Tamsulosin: current clinical experience O’Leary, Michael P
 2001
 1-20 6S1 p. 42-48
7 p.
 artikel
192 Targeting bcl-2 gene to delay androgen-independent progression and enhance chemosensitivity in prostate cancer using antisense bcl-2 oligodeoxynucleotides Gleave, Martin E
 1999
 1-20 6S1 p. 36-46
11 p.
 artikel
193 Taxanes: an overview of the pharmacokinetics and pharmacodynamics Vaishampayan, Ulka
 1999
 1-20 6S1 p. 22-29
8 p.
 artikel
194 Terazosin, doxazosin, and prazosin: current clinical experience Akduman, Bulent
 2001
 1-20 6S1 p. 49-54
6 p.
 artikel
195 The clinical usefulness of percent free-PSA Partin, Alan W.
 1996
 1-20 6S1 p. 1-3
3 p.
 artikel
196 The comparison of clinical and histopathologic features of interstitial cystitis Hanus, T
 2001
 1-20 6S1 p. 131-
1 p.
 artikel
197 The effect of manual physical therapy in patients diagnosed with interstitial cystitis, high-tone pelvic floor dysfunction, and sacroiliac dysfunction Lukban, J
 2001
 1-20 6S1 p. 121-122
2 p.
 artikel
198 The effects of hydrodistention on bladder surface mucin Rofeim, O
 2001
 1-20 6S1 p. 130-
1 p.
 artikel
199 The effects of ovariectomy on and prostaglandin levels in the rabbit urinary bladder Nichol, P
 2001
 1-20 6S1 p. 112-
1 p.
 artikel
200 The efficacy of calcium glycerophosphate in the prevention of food-related flares in interstitial cystitis Bologna, R.A
 2001
 1-20 6S1 p. 119-120
2 p.
 artikel
201 The epidemiology of interstitial cystitis: is it time to expand our definition? Kusek, John W
 2001
 1-20 6S1 p. 95-99
5 p.
 artikel
202 The levator myorraphy repair for vaginal vault prolapse Lemack, Gary E
 2000
 1-20 6S1 p. 50-54
5 p.
 artikel
203 The molecular bridge to gene therapy Glode, L. Michael
 1994
 1-20 6S1 p. 81-88
8 p.
 artikel
204 The overactive bladder: Pharmacologic basis of drug treatment Andersson, Karl-Erik
 1997
 1-20 6S1 p. 74-84
11 p.
 artikel
205 The patient's perspective: Redefining end points Palmtag, Hans
 2004
 1-20 6S1 p. 17-20
4 p.
 artikel
206 The patient with an overactive bladder—Symptoms and quality-of-life issues Jackson, Simn
 1997
 1-20 6S1 p. 18-22
5 p.
 artikel
207 The psychosocial economic impact of invisible chronic disease: examining the experience of patients with interstitial cystitis Azevedo, K
 2001
 1-20 6S1 p. 118-
1 p.
 artikel
208 The role of free/total prostate-specific antigen ratio in the prediction of final pathologic stage for men with clinically localized prostate cancer Pannek, Jürgen
 1996
 1-20 6S1 p. 51-54
4 p.
 artikel
209 The role of radiotherapy in themanagement of locally advanced prostate cancer Porter, Arthur T.
 1994
 1-20 6S1 p. 43-46
4 p.
 artikel
210 The role of the urologist in adjuvant chemotherapy trials for prostate cancer Presti Jr., Joseph C
 1999
 1-20 6S1 p. 47-50
4 p.
 artikel
211 The tension-free vaginal tape procedure for the treatment of stress incontinence in the female patient Carlin, Bruce I
 2000
 1-20 6S1 p. 28-31
4 p.
 artikel
212 The urothelium in overactive bladder: Passive bystander or active participant? de Groat, William C.
 2004
 1-20 6S1 p. 7-11
5 p.
 artikel
213 Title page 2007
 1-20 6S1 p. i-
1 p.
 artikel
214 To study the effect of hydrodistention on bladder mucosa and submucosa Mishra, N
 2001
 1-20 6S1 p. 126-
1 p.
 artikel
215 Transvaginal therapy of genuine stress incontinence Koduri, Sumana
 2000
 1-20 6S1 p. 23-27
5 p.
 artikel
216 Treatment of interstitial cystitis with montelukast, a leukotriene D4 receptor antagonist Bouchelouche, K
 2001
 1-20 6S1 p. 118-
1 p.
 artikel
217 Update on extracorporeal magnetic innervation (ExMI) therapy for stress urinary incontinence Galloway, Niall T.M
 2000
 1-20 6S1 p. 82-86
5 p.
 artikel
218 Update on nocturia: The best of rest is sleep Marschall-Kehrel, Daniela
 2004
 1-20 6S1 p. 21-24
4 p.
 artikel
219 Urgency: The cornerstone symptom of overactive bladder Brubaker, Linda
 2004
 1-20 6S1 p. 12-16
5 p.
 artikel
220 Urinary substance P concentration correlates with urinary frequency and urgency in interstitial cystitis patients treated with intravesical dimethyl sulfoxide and not intravesical anesthetic cocktail Kushner, L
 2001
 1-20 6S1 p. 129-
1 p.
 artikel
221 Urine markers of interstitial cystitis Erickson, Deborah R
 2001
 1-20 6S1 p. 15-21
7 p.
 artikel
222 Uropathogenic escherichia coli: interactions with bladder epithelium Hultgren, S.J
 2001
 1-20 6S1 p. 105-106
2 p.
 artikel
223 Urothelial function reconsidered: a new role in urinary protein secretion Deng, F.-M
 2001
 1-20 6S1 p. 117-
1 p.
 artikel
224 Usefulness of the ratio free/total prostatespecific antigen in addition to total PSA levels in prostate cancer screening Reissigl, Andreas
 1996
 1-20 6S1 p. 62-66
5 p.
 artikel
225 Use of algorithms as determinants for individual patient decision making: national comprehensive cancer network versus artificial neural networks Crawford, E.DAVID
 2003
 1-20 6S1 p. 13-19
7 p.
 artikel
226 Use of bone anchors in female urology Winters, J.Christian
 2000
 1-20 6S1 p. 15-22
8 p.
 artikel
                             226 gevonden resultaten
 
 Koninklijke Bibliotheek - Nationale Bibliotheek van Nederland